Gina M. Wallar's most recent trade in Neogenomics Inc. was a trade of 28,506 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on March 1, 2022.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Neogenomics Inc | Gina M. Wallar | President, Pharma Services | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 28,506 | 28,506 | - | - | Stock Option (Right to Buy) | |
| Neogenomics Inc | Gina M. Wallar | President, Pharma Services | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 11,677 | 33,443 (0%) | 0% | 0 | Common Stock | |
| Neogenomics Inc | Gina M. Wallar | President, Pharma Services | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Dec 2021 | 15,286 | 21,299 (0%) | 0% | 0 | Common Stock | |
| Neogenomics Inc | Gina M. Wallar | President, Pharma Services | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jul 2021 | 10,126 | 10,126 | - | - | Stock Option (Right to Buy) | |
| Neogenomics Inc | Gina M. Wallar | President, Pharma Services | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jul 2021 | 1,896 | 6,013 (0%) | 0% | 0 | Common Stock |